FEZF1 and metastatic malignant neoplasm in the lymph nodes: In patients diagnosed with lymph node metastases, the relative mean expression of FEZF1-AS1 was over 2.30 fold higher than that in patients without metastases (0.00076 ± 0.00020 vs.0.00033 ± 0.00006).